Enanta Pharmaceuticals (ENTA) Common Equity (2012 - 2026)

Enanta Pharmaceuticals has reported Common Equity for 15 years, with the latest figure at $116.6 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 24.64% year-over-year to $116.6 million; the trailing twelve-month figure through Mar 2026 stood at $116.6 million (up 24.64% YoY), and the FY2025 full-year result was $64.7 million, down 49.76% from the prior year.
• Common Equity for Q1 2026 stood at $116.6 million, down from $126.6 million in the prior quarter.
• The five-year high for Common Equity was $358.6 million in Q1 2022, with the low at $64.7 million in Q3 2025.
• Historically, Common Equity has averaged $192.4 million across 5 years, with a median of $166.1 million in 2024.
• Annual changes were most pronounced in 2025 — Common Equity sank 49.76% — and 2026, when it increased 24.64%.
• Enanta Pharmaceuticals' Common Equity stood at $300.8 million in 2022, then sank by 36.22% to $191.9 million in 2023, then sank by 41.73% to $111.8 million in 2024, then grew by 13.21% to $126.6 million in 2025, then fell by 7.9% to $116.6 million in 2026.
• The last three Common Equity figures came in at $116.6 million (Q1 2026), $126.6 million (Q4 2025), and $64.7 million (Q3 2025), per Business Quant data.